Table 1.
Completed and published CAR T cell therapy clinical trials in PDAC
| Trial number | Phase | Target | Stimulatory domain | Number of individuals with PDAC (total) | Preconditioning | Cell infusion number; treatment frequency | Efficacy in PDAC (total) | Reference |
|---|---|---|---|---|---|---|---|---|
| NCT02541370 | I | CD133 | anti-CD133 scFv-CD137-CD3z | 7 (23) | nab-paclitaxel (150 mg/m2) cyclophosphamide (30 mg/kg) |
0.5–2 × 10⁶/kg cells; 2–4 cycles | PR 2 (3) SD 3 (14) PD 2 (6) |
Wang et al.44 |
| NCT01869166 | I | EGFR | anti-EGFR scFv-CD8a-CD137-CD3z | 16 (16) | nab-paclitaxel (100–200 mg/m2) cyclophosphamide (15–35 mg/kg) |
3.48 × 10⁶/kg; 25 cycles/6 months | PR 4 (4) SD 8 (8) PD 2 (2) |
Liu et al.45 |
| NCT01935843 | I | HER2 | anti-HER2 scFv-CD8a-CD137-CD3z | 2 (11) | nab-paclitaxel (100–200 mg/m2) cyclophosphamide (15–35 mg/kg) |
2.1 × 10⁶/kg, 1–2 cycles | PR 0 (1) SD 0 (5) PD 2 (5) |
Feng et al.49 |
| NCT01897415 | I | MSLN | anti-MSLN scFv-4-1BB-CD3z | 6 (6) | N/A | NA; 3 cycles 3 times/week for 3 weeks | SD 2 (2) PD 1 (1) Unknown 3 (3) |
Beatty et al.39 |
| NCT02159716 | I | MSLN | anti-MSLN scFv-4-1BB-CD3z | 5 (15) | with or without cyclophosphamide (1.5 g/m2) | 1–3 × 10⁷ or 1–3 × 10⁸ cells; 1 cycle | SD not specified (11) | Haas et al.40 |
PR, partial response; SD, stable disease; PD, progressive disease; MSLN, mesothelin; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; PDAC, pancreatic ductal adenocarcinoma, N/A, not available.